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Abstract: PRDM1 (BLIMP1) is a transcription repressor protein shown to be involved in B-cell differentiation into 
plasma cells. Marginal zone lymphomas (MZL) and lymphoplasmacytic lymphomas (LPL) are B cell lymphomas that 
both show some degree of plasmacytic differentiation and thus can sometimes constitute a difficult differential 
diagnosis. In this study, we investigated if MZL and LPL have abnormalities in the expression of PRDM1 beta and 
if there are any differences in expression between these two entities. After interrogating 42 samples (15 marginal 
zone lymphomas, 9 lymphoplasmacytic lymphomas, 3 follicular lymphomas, and 13 normal/control samples), we 
have found that a significant percentage of MZL and LPL cases harbor abnormalities (67% and 44%, respectively) 
involving the PRDM1-β transcript (P=0.004). By immunohistochemistry, PRDM1 positive staining (>5%) was more 
common in MZL. We conclude that PRDM1-β may play a role in the pathogenesis of these low-grade lymphomas 
with plasmacytic differentiation.
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Introduction
Positive regulatory domain containing 1 with 
zinc-finger domain (PRDM1/BLIMP) located on 
chromosome 6q21-22.1 has been cited as the 
“master regulator” of B cell and plasma cell dif-
ferentiation. PRDM1 encodes a 98 kDa protein 
that represses beta-interferon gene expression 
via PRDI promoter binding. Alternative splicing 
leads to 2 variant isoforms: PRDM1α, which is 
a tumor suppressor and PRDM1β, which lacks 
the ability to repress transcription. Compared 
to PRDM1α, PRDM1β lacks exons 1-3 and the 
amino-terminal 101 amino acids. It also lacks 
the PR domain of PRDM1α. Both α and β iso-
forms have shown to be involved in B cell dif-
ferentiation into plasma cells [1]. More specifi-
cally, PRDM1 has been shown to up-regulate 
syndecan-1 (CD138) in transfected B cell lym-
phoma cell lines [2]. Furthermore, PRDM1β is 
expressed in germinal center B-cells that have 
committed to plasmacytic differentiation [3]. 
PRDM1 expression is repressed by BCL-6 in 
mature B cells and promotes plasmacytic dif-
ferentiation by repressing PAX5 and allowing 
expression of XBP-1 [4, 5].
PRDM1 was first described in 1991 as a novel 
repressor of beta interferon [6]. It was formally 
described in 1994 as B lymphocyte induced 
maturation protein (BLIMP1), a transcription 
repressor protein. There have been a number of 
studies looking at the role PRDM1 plays in vari-
ous B-lineage lymphoid malignancies. Several 
papers have described the role of PRDM1 
mutations in the pathogenesis of diffuse large 
B-cell lymphomas (DLBCL) [7, 8]. Furthermore, 
PRDM1 mutations are associated with incre- 
ased chemotherapy resistance to regimens 
lacking Rituxan [9]. Previous publications also 
show a relationship between treatment res- 
ponse and PRDM1-β expression levels in man-
tle cell lymphoma (MCL) [10]. In multiple myelo-
ma cases, PRDM1 is reported to be functionally 
impaired [11]. PRDM1 has also been shown to 
be downregulated in other lymphomas such as 
PRDM1 in MZL and LPL
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firm the diagnosis. For the immunohistochemi-
cal portion of the study, cases of MZL and LPL 
from 2005-2008 were identified by searching 
the Copath database of the Division of Anato- 
mic Pathology and BJH databases. Cases of 
nodal, extranodal, and splenic marginal zone 
lymphoma were included. Normal control cases 
included bone marrow samples which showed 
no involvement by B cell lymphoma, reactive 
lymph nodes, benign spleen, and benign tonsil-
lar tissue.
Nucleic acid extraction and reverse transcrip-
tase polymerase chain reaction
RNA extractions were performed by triazol 
reagent. A DNase treatment was performed on 
the RNA prior to reverse transcriptase-PCR 
(RT-PCR). RT-PCR was performed using previ-
ously published primers for PRDM1-β [9]. This 
generated cDNA that was run on a 4% agarose 
gel. A one step RT-PCR method was used 
according to manufacture protocol. The expect-
ed transcript length was 264 base pairs. 
Different length bands or absent bands are 
reported as abnormal. RT-PCR for beta-actin 
was performed on all cases to ensure sample 
RNA integrity.
PCR product purification and sequencing 
PCR products from select abnormal cases with 
different length bands were purified and 
sequenced. PCR products from select cases 
with normal bands were also purified and 
sequenced to ensure target fidelity. This was 
performed with standard manufacture protocol 
for the Qiagen. Purified PCR products were 
sequenced by traditional Sanger method.
Immunohistochemistry
Immunohistochemical staining was optimized 
using an antibody directed to both PRDM1α 
NK/T cell lymphoma [12] and anaplastic large T 
cell lymphoma [13].
Marginal zone lymphoma (MZL) comprises 
three major classes of lymphoproliferative dis-
eases, namely splenic MZL, nodal MZL, and 
extranodal MZL (MALT lymphomas) [14]. To- 
gether they constitute 5-17% of all non-Hodgkin 
lymphomas and are generally considered indo-
lent neoplasms. However, when stratified by 
risk levels, 5-year overall survival ranges from 
56-100% [15]. Lymphoplasmacytic lymphoma 
(LPL) is a relatively rare entity (incidence of 8 
per 1 million; 1% of hematologic malignancies) 
comprising of small B-cells, plasmacytoid lym-
phocytes, and plasma cells and is, as such, a 
diagnosis of exclusion [14]. LPL is often accom-
panied by an IgM paraprotein and is indolent in 
behavior with a prognosis similar to nodal MZL 
but better than extranodal MZL. Since both 
lymphomas are those of small B cells of post-
germinal center derivation with many cases of 
MZL showing plasmacytic differentiation, the 
distinction between these two entities can be 
challenging. More recently, mutations in 
MYD88 have been described in 90% of LPL, 
but these mutations have also been described 
in cases of MZL [16]. Even in the hands of 
experts, consensus is found in only about half 
of cases. In some cases, the distinction is so 
unclear as to generate a generic diagnosis of 
small B-cell lymphoma with plasmacytic differ-
entiation despite adequate immunohistochem-
ical, flow cytometric, and clinical work up [17, 
18]. 
In this study, we evaluate the pattern and ext- 
ent of PRDM1 expression in lymphomas with 
plasmacytic differentiation, namely marginal 
zone lymphomas (MZL) and lymphoplasma- 
cytic lymphoma (LPL).
Table 1. Demographic and sample characteristics
Number 
of cases 




Mean Percent  
involvement  
by FC (Range) 
FL 3 62 (57-69) 2:1 30% (<1%-51%) 
LPL 9 62 (51-79) 2:7 10% (<1%-46%)
MZL 15 67 (50-87) 5:10 31.5% (1.2%-86%)
NL/Other 12 14-73 N/A N/A
FC = Flow Cytometry; FL = Follicular Lymphoma, LPL = lymphoplas-




Permission for the study was granted by 
the Washington University Human Studies 
Committee. Sequentially archived snap 
frozen shed flow cytometric samples with 
the diagnosis of MZL or LPL were selected 
from the Barnes-Jewish Hospital flow 
cytometry archives from materials receiv- 
ed between 2007-2010. All cases were 
reviewed by 2 hematopathologists to con-
PRDM1 in MZL and LPL
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for percentage nuclear staining in the lympho-
cytes. Staining was performed at 1:4 dilution 
(all cases). Cases with weaker or equivocal 
staining were rerun at a 1:2 dilution (13 cases). 
The higher of percentage staining between dilu-
tions was adopted. In addition, two normal 
bone marrow core biopsies in patients with a 
history of plasma cell neoplasm and eight 
and PRDM1β due to the lack of a PRDM1 spe-
cific antibody. A BLIMP1 antibody (3H2-E8 
clone, Novus Biologics) was optimized and anti-
gen retrieval was performed using a CC1 stan-
dard protocol (1 mM EDTA pH 8.0). Staining was 
performed on a BenchMark XT IHC/ISH Staining 
Module, and detection was performed with XT 
ultraView DAB v3. Slides were manually graded 
Figure 1. A. Beta-actin control showing confirmed intact RNA for amplification in all samples. B. Abnormal bands 
are seen in select lanes of LPL and MZL along with one normal control. Complete loss of PRDM1 transcript is iden-
tified in several lanes representing cases of MZL on sample gel (Follicular lymphoma, LPL = lymphoplasmacytic 
lymphoma, MZL = marginal zone lymphoma, NL = normal control).
PRDM1 in MZL and LPL
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cases and 1 LPL case (Figure 1). PCR and cyto-
genetic results are summarized in Table 2. 
Overall, 67% of MZL and 44% of LPL showed 
either loss or abnormal PRDM1-β transcript. All 
cases that were initially diagnosed as normal 
but subsequently reclassification showed ab- 
normalities in PRDM1-β expression. PRDM1-β 
abnormalities were more common in MZL and 
LPL compared to normal cases (P=0.0043). 
Sequencing of RT-PCR products from cases 
with only the wild-type 264 base pair band con-
firmed wild-type PRDM1-β sequence at the 
tested locus. Abnormal bands from a select 
LPL and MZL case were sequenced which both 
mapped to PRDM1 region with greater than 
90% homology. A single normal case showed 
an additional abnormal band. The forward read 
did not map to PRDM1 and thus the product is 
presumed to be non-specific. 
Recurrent abnormalities involving the same 
predicted splice site were also observed. A 
recurrent splice site variant at position -44 
and -45 of the PRDM1-β transcript lying in the 
5’UTR region was observed in 3 of the cases (2 
MZL and 1 LPL). Predictions regarding splicing 
involving the promoter region were made based 
on interrogating the splice site mutation with 
two separate prediction software drosophila 
and SIFT. However, the splice site mutation 
does not appear to impact a change to the 
protein.
Cytogenetic data was available for 5 of the 
malignant cases. A t(14;18) was detected in 
one follicular lymphoma. Del11q21 and del 13 
were reported by an outside institution in one 
case of LPL. Two other LPL cases and one MZL 
case showed normal karyotype. No cases 
showed a deletion involving 6q. Since the 
cohort for PCR and IHC studies were different, 
benign tonsil specimens were included as con-
trols. Five percent or less tumor staining was 
considered negative.
Data analysis
The sequenced PCR product were aligned using 
Basic Local Alignment Search Tool (BLAST®) to 
interrogate for small deletions, insertions, sub-
stitutions, and transcripts of abnormal length. 
Statistical analysis was performed using a two-
tailed Fischer t-test.
Results
Our search yielded 39 patient samples in total. 
The samples included 27 malignant cases 
comprising of 3 Follicular Lymphoma (FL), 9 
LPL, 15 MZL (4 splenic MZL, 3 nodal MZL, 4 
extra-nodal MZL, and 6 not further classified). 
10 normal controls were initially evaluated, 
comprising of 3 reactive lymph nodes, 1 sple-
nomegaly spleen sample, and 6 bone marrows; 
however two bone marrow cases were reclassi-
fied as indeterminate after review leaving 8 nor-
mal controls for comparison. In one case, a 
minute plasma cell clone of unknown signifi-
cance was detected. In the other case, multiple 
lymphoid aggregates were noted in a patient 
with a history of MZL. Though initially favored to 
be benign, subsequent testing and involvement 
at various other sites was suggestive of bone 
marrow involvement. Demographic and speci-
men data is summarized in Table 1. 
RT-PCR and sequencing
All follicular lymphomas showed a single 264 
base pair band consistent with the wild-type 
PRDM1 transcript (3/3). An extra abnormal 
band was seen in 4 LPL cases, 3 MZL, and 1 
normal (NL) case. Complete loss of the PRDM1 
transcript (no band) was detected in 5 MZL 
Table 2. Summary of RT-PCR results and cytogenetic data
Number  
of cases





loss Cytogenetics (#of cases)
FL 3 3 0 0 t(14;18) (1)
LPL 9 5 3 1 Normal (2); Del11q21 and del 13 (1)
MZL 15 5 5 5 Normal (1) 
NL 13 9 1 0 ----
Other 2 0 2 0 Normal (1)
(FL = Follicular Lymphoma, LPL = lymphoplasmacytic lymphoma, MZL = marginal zone lymphoma, NL = normal control).
PRDM1 in MZL and LPL
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mantle zone lymphocytes were clearly nega- 
tive while interfollicular plasma cells and a sub-
set of germinal center cells showed positive 
staining. Demographics and staining results 
are summarized in Table 3. 
Discussion
PRDM1 has previously been implicated in the 
pathogenesis and treatment response of B-cell 
lymphoid neoplasms such as Burkitt Lympho- 
analysis was limited in that correlative compari-
sons between PCR, cytogenetics, and immu-
nostaining were not possible. 
Immunohistochemistry
A total of 20 lymphoma cases were available 
for review comprising of 12 male and 8 female 
patients with a median age of 66 years (range 
48-87 years). Twelve of the cases were MZL 
(60%) and 8 cases were LPL (40%). Four of 12 
Figure 2. Immunohistochemical staining with PRDM1: A. Marginal zone lymphoma (100×, Olympus BX51); B. Lym-
phoplasmacytic lymphoma (40×); C. Lymph node positive control (100×); D. Normal bone marrow negative control 
(40×).
Table 3. Summary of demographics and immunohistochemical 











Mean% lymphocyte  
staining in  
(+) cases
MZL 12 71 (52-87) 6:6 33% (4/12) 16% (range 10-25%)
LPL 8 61 (48-79) 6:2 0% (0/8) 0%
Normal BM 2 63 (62-63) 2:0 0% (0/2) 0%
MZL cases (33%) but none of 
the LPL cases 0/8 showed 
positive staining for PRDM1 
(P=0.116) (Figure 2). Though 
this was not statistically sig-
nificant given the small sam-
ple size, a trend for increased 
immunostaining was seen. 
Both the bone marrow cores 
showed no staining (0/2). In 
the benign lymph nodes, the 
PRDM1 in MZL and LPL
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clarifying PRDM1’s precise role in lympho- 
magenesis. 
Deletion in 6q is a known common abnormality 
seen in lymphoid malignancies [26]. While the 
loss of PRDM1 may be responsible for the 
pathogenesis in some of the cases with 6q 
deletion, other mechanisms are likely at play 
given that nearly half of cases will not demon-
strate deletion of 6q. Whole genome survey for 
copy number alterations may have shed light in 
this regard, but remained a limitation for this 
study due to the lack of additional material. In 
ocular adnexal marginal zone B cell lymphoma, 
TNFAIP3 was identified as the target gene in 
cases of loss at adjacent 6q23.3-q24.1 loci 
[27]. A negative regulator of nuclear factor-kap-
pa B (NF-kappaB), TNFAIP3 was deleted in 
other lymphoid malignancies such as DLBCL 
and MCL [28]. In DLBCL, deletions of either 
PRDM1 or TNFAIP3 were seen, but not both, 
would be deleted in a homozygous manner 
[29]. The possibility of functional synergism 
between PRDM1 and the TNFAIP3 gene prod-
uct may also be considered in MZL and LPL [5]. 
In many of the cases in our cohort, an abnor-
mally sized band was identified rather than co- 
mplete loss of the transcript. Sanger sequenc-
ing identified various mutations to account for 
the change in transcript size including single 
base pair deletions and single base pair substi-
tutions. Interestingly, a recurrent splice site 
variant was identified affecting the promoter 
region in the 5’UTR of the PRDM1 transc- 
ript. The functional significance of these genet-
ic alterations are unclear without in vitro stud-
ies, but one may postulate that alternative 
splicing may result in a qualitative defect of the 
translated protein providing a mechanism for 
‘functional deletion’. This proposes a possible 
mechanism leading to down regulation of 
PRDM1 in these B cell lymphomas. 
In this study, PRDM1 staining (>5%) was more 
frequently positive in MZL than LPL. While 
absent staining was seen in LPL, loss by immu-
nohistochemistry did not correlate with loss of 
the PRDM1 transcript in our PCR experiments. 
This may be the result of non-specificity of the 
PRDM1 antibody derived from the 3H2-E8 cell 
line which was raised using murine PRDM-1 
residues 199-409. The antibody did not dem-
onstrate specificity for the beta transcript like 
the primer used for RT-PCR. The use of an 
ma (BL), DLBCL, MCL, and MM [19]. Further- 
more PRDM1 has been shown to function as a 
tumor suppressor in B cell lymphomas [18]. As 
a key regulator of plasma cell differentiation in 
B-cells, we sought to investigate the patterns of 
expression and role of PRDM1-beta in B-cell 
lymphomas associated with plasmacytic differ-
entiation, namely MZL and LPL. 
We found that in 67% and 44% of cases of MZL 
and LPL, respectively, there was some type of 
aberration of the PRDM1-β transcript. These 
aberrations consisted of either complete loss 
of the transcript seen in 33% and 11% of MZL 
and LPL cases, respectively, or an abnormally-
sized transcript (33% for both). In these cases, 
complete transcript loss may be the result of 
deletions involving PRDM1 (located on 6q21, 
Ensembl) or epigenetic mechanisms resulting 
in silencing of PRDM1 expression. Though 
available cytogenetic data was limited, no loss 
of 6q was detect in any of the cases implying 
the presence of a microdeletion. Cryptic dele-
tions of 6q21 have been previously reported in 
MZL (14%-16% of cases) and were associated 
with a switch to high grade histology (predomi-
nant large cell or blast component) [20]. In fact, 
del6q has been identified as one of the pre-
dominant aberrations in splenic MZL (11%) 
though an association with survival has not 
been described [21, 22]. With regards to lym-
phoplasmacytic lymphoma, del6q has been 
cited as the most frequent copy number altera-
tion in Waldenstrom macroglobulinemia (WM) 
with rates of detection based on various meth-
odologies (conventional cytogenetics, FISH, 
array CGH, SNP) ranging from 22% to 42% [23]. 
In WM, del6q may be a poor prognostic factor 
[24]. There is variability in the minimal deleted 
region due to involvement of large fragments of 
6q. Putative tumor suppressor genes in this 
region include TNFAIP3 and PRDM1 [24, 25]. 
The frequency of PRDM1 loss in our study is 
lower than that cited in the literature for LPL, 
though this may be due to our small sample 
size. Furthermore, since primers targeted only 
the beta transcript (not alpha), it is possible 
that we are underestimating the loss PRDM1 
mRNA transcripts in this study. Based on fre-
quent loss in MZL, PRDM1 may serve as a ratio-
nal candidate gene for disease pathogenesis in 
MZL as well as LPL. Functional and animal stud-
ies with knock-out models, are likely to aid in 
PRDM1 in MZL and LPL
8616 Int J Clin Exp Pathol 2017;10(8):8610-8618
PRDM1 indicates a tumor-suppressor role in 
diffuse large B-cell lymphomas. Blood 2006; 
107: 4090-100.
[2] Turner CA Jr, Mack DH and Davis MM. Blimp-1, 
a novel zinc finger-containing protein that can 
drive the maturation of B lymphocytes into im-
munoglobulin-secreting cells. Cell 1994; 77: 
297-306.
[3] Cattoretti G, Angelin-Duclos C, Shaknovich R, 
Zhou H, Wang D and Alobeid B. PRDM1/
Blimp-1 is expressed in human B-lymphocytes 
committed to the plasma cell lineage. J Pathol 
2005; 206: 76-86.
[4] Boi M, Zucca E, Inghirami G, Bertoni F. PRDM1/
BLIMP1: a tumor suppressor gene in B and T 
cell lymphomas. Leuk Lymphoma 2015; 56: 
1223-8.
[5] Hangaishi A and Kurokawa M. Blimp-1 is a tu-
mor suppressor gene in lymphoid malignan-
cies. Int J Hematol 2010; 91: 46-53.
[6] Keller AD and Maniatis T. Identification and 
characterization of a novel repressor of beta-
interferon gene expression. Genes Dev 1991; 
5: 868-879.
[7] Mandelbaum J, Bhagat G, Tang H, Mo T, Brah-
machary M, Shen Q, Chadburn A, Rajewsky 
K, Tarakhovsky A, Pasqualucci L and Dalla-Fav-
era R. BLIMP1 is a tumor suppressor gene fre-
quently disrupted in activated B cell-like dif-
fuse large B cell lymphoma. Cancer Cell 2010; 
18: 568-579.
[8] Wagner SD, Ahearne M and Ko Ferrigno P. The 
role of BCL6 in lymphomas and routes to ther-
apy. Br J Haematol 2011; 152: 3-12.
[9] Liu YY, Leboeuf C, Shi JY, Li JM, Wang L, Shen 
Y, Garcia JF, Shen ZX, Chen Z, Janin A, Chen SJ 
and Zhao WL. Rituximab plus CHOP (R-CHOP) 
overcomes PRDM1-associated resistance to 
chemotherapy in patients with diffuse large B-
cell lymphoma. Blood 2007; 110: 339-344.
[10] Desai S, Maurin M, Smith MA, Bolick SC, Des-
sureault S, Tao J, Sotomayor E and Wright KL. 
PRDM1 is required for mantle cell lymphoma 
response to bortezomib. Mol Cancer Res 
2010; 8: 907-918.
[11] Ocana E, Gonzalez-Garcia I, Gutierrez NC, Mo-
ra-Lopez F, Brieva JA and Campos-Caro A. The 
expression of PRDI-BF1 beta isoform in multi-
ple myeloma plasma cells. Haematologica 
2006; 91: 1579-1580.
[12] Liang L, Nong L, Zhang S, Zhao J, Ti H, Dong Y, 
Zhang B and Li T. The downregulation of 
PRDM1/Blimp-1 is associated with aberrant 
expression of miR-223 in extranodal NK/T-cell 
lymphoma, nasal type. J Exp Clin Cancer Res 
2014; 33: 7.
[13] Boi M, Rinaldi A, Kwee I, Bonetti P, Todaro M, 
Tabbo F, Piva R, Rancoita PM, Matolcsy A, Ti-
mar B, Tousseyn T, Rodriguez-Pinilla SM, Piris 
aptamer with specificity for the beta variant 
may circumvent this limitation. Furthermore, 
despite titration of antibody at various dilu-
tions, most cases showed only a light blush of 
staining in positive cells in order to obtain low 
background, making grading of staining in the 
lymphoma cases subjective. Higher concentra-
tion of antibody may have demonstrated posi-
tivity in LPL cases, but at the cost of increasing 
non-specific background staining making reli-
able grading infeasible. Other studies, which 
have used immunohistochemistry, have shown 
PRDM1 expression in LPL plasma cells app- 
eared to be lower in comparison to marginal 
zone lymphoma and myeloma, however they 
were not able to achieve statistical significance 
[30].
Overall, this study implicates altered PRDM1 
expression in the pathogenesis of lymphomas 
with plasmacytic differentiation, namely LPL 
and MZL. This is congruent with gene expres-
sion studies, which have shown lower PRDM1 
expression in lymphoplasmacytic lymphoma 
[31]. Alterations in PRDM1 are biologically 
rational in this regard, considering that loss of a 
factor driving B-cell differentiation to plasma 
cells could well account for absence of full plas-
macytic differentiation in the B-cells that com-
prise these neoplasms. FISH or sequencing of 
cases with total PRDM1 loss may help differen-
tiate between epigenetic mechanisms versus 
deletions in these cases. Importantly, it will be 
useful to analyze clinical outcomes in patients 
with PRDM1 aberrations as well as investigate 
propensity to progress to DLBCL so as to deter-
mine the clinical significance of our findings. 
Finally, in-vitro and murine models may provide 
clarification with regards to the true biologic 
role of PRDM1 in low-grade lymphomas with 
plasmacytic differentiation. 
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